Company intelligence / Profile preview

DxLab

Somerville, Massachusetts, United Statesdxlabsuite.com ↗

Ownership: Private
Development stage: Commercial

Overview

DxLab has developed a rapid, high-throughput point-of-care diagnostic platform capable of detecting pathogens such as SARS-CoV-2 in as little as 10 minutes. Their COVID testing system received FDA Emergency Use Authorization. The platform is adaptable to new targets and indications, with additional assays under development.

Therapeutic areas: Infectious Diseases
Modalities: DeviceNucleic acid amplification-based diagnostic testIn vitro diagnostic assay
Industry: Molecular Diagnostics

Partnerships

Axxin (diagnostic device engineering partner)

Beyond the preview

Go deeper on DxLab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DxLab.

Explore the full profile